论文部分内容阅读
目的研究糖皮质激素治疗过敏性紫癜的临床疗效,分析白细胞三烯(LTB4)与可溶性血管细胞黏附分子-1(sVCAM-1)水平变化情况。方法将在该院接受治疗的过敏性紫癜患者174例作为研究对象,应用数字随机法将其分为对照组与实验组,所有患者均接受相同的常规治疗,实验组的患者在常规治疗的基础上给予氢化可的松治疗,对比分析两组患者的治疗效果和LTB4与sVCAM-1水平变化情况。结果实验组患者的临床治疗总有效率为81.82%明显优于对照组的58.14%(P<0.05);治疗后两组患者的LTB4与sVCAM-1水平均有所降低,但实验组患者的LTB4与sVCAM-1水平明显低于对照组,差异有统计学意义(P<0.05)。结论在常规治疗的基础上应用糖皮质激素能够显著改善过敏性紫癜患者的临床症状,有效抑制炎症发生,临床疗效更佳,可在过敏性紫癜的临床治疗中进行推广应用。
Objective To study the clinical efficacy of glucocorticoid in the treatment of Henoch-Schonlein purpura and to analyze the changes of leukotriene (LTB4) and soluble vascular cell adhesion molecule-1 (sVCAM-1) levels. Methods A total of 174 patients with allergic purpura treated in the hospital were selected as the study subjects. They were divided into control group and experimental group by digital randomization method. All patients received the same routine treatment. The patients in the experimental group were treated on the basis of routine treatment On hydrocortisone treatment, comparative analysis of two groups of patients with treatment and LTB4 and sVCAM-1 levels. Results The total effective rate of clinical treatment in experimental group was 81.82%, which was significantly better than that in control group (58.14%, P <0.05). The levels of LTB4 and sVCAM-1 in both groups decreased after treatment, but LTB4 And sVCAM-1 levels were significantly lower than the control group, the difference was statistically significant (P <0.05). Conclusion The application of glucocorticoid on the basis of routine treatment can significantly improve the clinical symptoms of patients with allergic purpura, effectively inhibit the occurrence of inflammation, better clinical efficacy, in the clinical treatment of allergic purpura popularization and application.